Hikma Pharmaceuticals Plc Director Declaration (0008D)

TIDMHIK

RNS Number : 0008D

Hikma Pharmaceuticals Plc

23 January 2015

Dr. Pamela Kirby Appointment to Reckitt Benckiser Group plc

London, 23 January 2015 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) makes this announcement in accordance with Listing Rule LR 9.6.14, which requires Hikma to notify the market when directors of Hikma become directors of other publicly traded companies.

Dr. Pamela Kirby, an independent non-executive director of Hikma, has been appointed as an independent non-executive director of Reckitt Benckiser Group plc (LSE: RB) with effect from 10 February 2015.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

   Peter Speirs, Company Secretary                       +44 (0)20 7399 2760

Notes to Editors

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNBJMBTMBITBTA

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024